Lauren P Silvernail
CIK 1225755 · See Remarks · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RVNC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE #100
IRVINE, CA 92618
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HROW | Director | 1,000 | $27.47 | $27.5K | $31.0K | 2 | 2026-06-22 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $0 | 3 | 2026-02-10 |
| HARROW, INC. (HROWM) Delisted | Director | — | $26.03 | — | $0 | 3 | 2025-06-24 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 4 | 2024-03-11 |
| EOLS | See Remarks | 141,571 | $6.98 | $988.2K | -$1.03M | 12 | 2022-05-18 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO & CBO | 65,497 | $3.65 | $239.1K | -$2.31M | 25 | 2018-05-24 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Chief Financial Officer | 177,709 | — | — | $21.4K | 21 | 2012-05-10 |
Recent Filings · Page 7 of 8
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-02-18 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −513 | -$2.0K | EDGAR |
| 2010-02-10 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −962 | -$3.5K | EDGAR |
| 2010-02-05 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −989 | -$3.6K | EDGAR |
| 2010-02-04 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Mixed | +8,231 | -$2.8K | EDGAR |
| 2009-02-05 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Grant (A) | +9,000 | $9 | EDGAR |
| 2008-12-11 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Buy (P) | +17,000 | $10.7K | EDGAR |
| 2008-03-05 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Tax (F) | −747 | -$3.9K | EDGAR |
| 2008-02-20 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Tax (F) | −500 | -$2.3K | EDGAR |
| 2008-02-12 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Grant (A) | +10,500 | $10 | EDGAR |
| 2008-02-05 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Tax (F) | −831 | -$4.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.